Patents Assigned to INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES
-
Patent number: 9139543Abstract: The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.Type: GrantFiled: May 10, 2013Date of Patent: September 22, 2015Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Kunlun He, Junhai Xiao, Xinbo Zhou
-
Publication number: 20150203460Abstract: The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable salt, solvate or hydrate thereof. The present invention further relates to a method for preparing the compound, a pharmaceutical composition containing the compound, and a method or use thereof for prevention or treatment of neurodegenerative diseases.Type: ApplicationFiled: August 24, 2012Publication date: July 23, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Dan Han, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xinbo Zhou, Xingzhou Li, Xiaokui Wang, Dan Jiang, Wei Chen, Hongying Liu
-
Publication number: 20150141407Abstract: The present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, its preparation method, a pharmaceutical composition comprising the compound, and its use in manufacture of a medicament for treatment of a disease or disorder, wherein R1, R2, R5, R6, X, Y, Q, W, n1 and n2 are defined as those stated in the description.Type: ApplicationFiled: May 30, 2013Publication date: May 21, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lan Xie, Xiaofeng Wang, Kuo-Hsiung Lee
-
Patent number: 9034382Abstract: The present invention relates to an oseltamivir phosphate granule and preparation method thereof. The said granule comprises 1.97-19.8 wt. % oseltamivir phosphate, 75.0-97.5 wt. % diluent, 0.1-5.0 wt. % binder, optionally 1.0-5.0 wt. % edible flavoring essence, sweetener and/or edible pigment. It is prepared by using 30-55 v/v % aqueous ethanol solution as moistening agent. The granules prepared by the formulation and method according to the present invention have good uniformity and stability and are water-soluble. The administration dosage of the granules can be conveniently selected based on the age and body weight of patients. The oseltamivir phosphate granule is suitable for administering to old people, children and flu gravis patients and those patients that swallow inconveniently or difficulty. The preparation of the granule is simple and low in production cost.Type: GrantFiled: August 11, 2006Date of Patent: May 19, 2015Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Junhai Xiao, Yunde Xie, Xingzhou Li, Hao Cui, Zhibing Zheng
-
Publication number: 20150133556Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.Type: ApplicationFiled: October 10, 2014Publication date: May 14, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Song LI, Wu ZHONG, Zhibing ZHENG, Xinbo ZHOU, Junhai XIAO, Yunde XIE, Lili WANG, Xingzhou LI, Guoming ZHAO, Xiaokui WANG, Hongying LIU
-
Publication number: 20150119430Abstract: The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 10, 2013Publication date: April 30, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Kunlun He, Junhai Xiao, Xinbo Zhou
-
Topiramate Sustained-Release Pharmaceutical Composition, Method for Preparing Same, and Uses Thereof
Publication number: 20150099003Abstract: A sustained-release pharmaceutical composition of topiramate, which is free of binding agent. The sustained-release pharmaceutical composition of topiramate is a sustained-release pellet, comprising a blank pellet core, a drug layer, and a sustained-release coating layer.Type: ApplicationFiled: March 7, 2013Publication date: April 9, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang -
Publication number: 20150044295Abstract: The present invention provides a combination product, which comprises immediate release pellet of phentermine and sustained-release pellet of topiramate, wherein the pellet of topiramate includes: a) a blank pellet core; b) an active drug layer that contains topiramate and is free of binding agent, the layer being located on surface of the blank pellet core; c) a sustained-release coating layer containing ethyl cellulose and PVP K30, the sustained-release coating layer being located on external of the active drug layer. The present invention further discloses a method for preparing the combination product.Type: ApplicationFiled: March 20, 2013Publication date: February 12, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Chunseng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
-
Patent number: 8933106Abstract: The invention relates to 2-(4-Substituted phenylamino) polysubstituted pyridine compounds as inhibitors of non-nucleoside HIV reverse transcriptase, preparation methods and uses thereof. Specifically, the invention relates to compounds of formula I or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description. The compounds of formula I of the invention are a type of anti-HIV active compounds having new backbone structure.Type: GrantFiled: September 28, 2009Date of Patent: January 13, 2015Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lan Xie, Xingtao Tian, Kuo-Hsiung Lee, Shibo Jiang, Hong Lu
-
Patent number: 8846678Abstract: Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.Type: GrantFiled: August 2, 2011Date of Patent: September 30, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
-
Patent number: 8829001Abstract: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of a disease associated with central nervous system dysfunction, such as Parkinson's disease, schizophrenia, drug addiction and relapse, as well as kidney protection and immunoregulation, or as a tool for researching D3R function or diseases associated with D3R dysfunction.Type: GrantFiled: September 28, 2009Date of Patent: September 9, 2014Assignee: The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. ChinaInventors: Jin Li, Rifang Yang, Rui Song, Hui Zhu, Ning Wu, Liuhong Yun, Ruibin Su, Rusheng Zhao
-
Patent number: 8802669Abstract: Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds described herein in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the compounds of the general formula (I), the use of the compounds, an isomer thereof, a pharmaceutically acceptable salt thereof or a hydrate thereof as a medicament, in particular as a medicament for the treatment and/or prevention of Hepatitis B.Type: GrantFiled: May 27, 2010Date of Patent: August 12, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences, P.L.A. ChinaInventors: Song Li, Xiaoqian Xu, Guoming Zhao, Lili Wang, Hua Guan, Junhai Xiao, Wu Zhong, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xiaokui Wang, Xinbo Zhou, Hongying Liu
-
Patent number: 8759355Abstract: The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor ? (hPPAR?)-associated diseases and risk factors.Type: GrantFiled: July 18, 2008Date of Patent: June 24, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A.Inventors: Song Li, Yanbo Yang, Junhai Xiao, Wu Zhong, Zhibing Zheng, Xingzhou Li, Yunde Xie, Lili Wang, Hongying Liu
-
Publication number: 20140080840Abstract: Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound.Type: ApplicationFiled: December 6, 2011Publication date: March 20, 2014Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Hongliang Wang, Junhai Xiao, Xian Zhang, Lili Wang, Zhibing Zheng, Wu Zhong, Yunde Xie, Xingzhou Li, Xinbo Zhou, Guoming Zhao, Xiaokui Wang
-
Patent number: 8674136Abstract: Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection, is provided.Type: GrantFiled: May 16, 2011Date of Patent: March 18, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Ping Liu, Junhai Xiao, Zhibing Zheng, Yunde Xie, Guoming Zhao, Xiaokui Wang, Lili Wang, Xingzhou Li, Xinbo Zhou
-
Publication number: 20140057804Abstract: The present invention provides a cell model and a method for screening c-Fms tyrosine kinase inhibitors. Specifically, the present invention provides a cell that expresses macrophage colony stimulating factor receptor and STAT1 protein simultaneously. The present invention further provides a method for screening c-Fms tyrosine kinase inhibitors, a method for evaluating the inhibiting activity of a compound or a composition against c-Fms tyrosine kinase, and use of the cell in screening c-Fms tyrosine kinase inhibitors. The cell model established in the present invention is sensitive, highly effective and reliable, and can be used in high-throughput screening and/or high-content screening of c-Fms tyrosine kinase inhibitors.Type: ApplicationFiled: March 14, 2012Publication date: February 27, 2014Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lili Wang, Shengqian Yang, Long Long, Junhai Xiao, Song Li
-
Publication number: 20130331604Abstract: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.Type: ApplicationFiled: August 16, 2013Publication date: December 12, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A., ChinaInventors: Song Li, Wu Zhong, Zhibing Zheng, Xinbo Zhou, Junhai Xiao, Yunde Xie, Lili Wang, Xingzhou Ll, Guoming Zhao, Xiaokui Wang, Hongying Liu
-
Publication number: 20130310310Abstract: Disclosed are PEG-modified Exendin-4 analogs and uses thereof. In particular, disclosed are PEG-modified Exendin-4 analogs as shown in formula (I), i.e., PEG-M-X-(Ex-4), or pharmaceutically acceptable salts thereof, as well as Exendin-4 analogs as shown in formula (II), i.e., [Aap]Exendin-4, wherein the symbols are as defined in the specification. Further disclosed are methods for preparing PEG-modified Exendin-4 analogs, uses of PEG-modified Exendin-4 analogs, compositions comprising the same, as well as use of the Exendin-4 analogs in the preparation of the PEG-modified Exendin-4 analogs. In the PEG-modified Exendin-4 analogs, modification by polyethylene glycol occurs in a site-directed manner in the peptide chains of the Exendin-4 analogs. The PEG-modified Exendin-4 analogs can be used to prevent and/or treat diseases and/or symptoms related to decreased activity of GLP-1 receptors, such as type II diabetes.Type: ApplicationFiled: August 11, 2011Publication date: November 21, 2013Applicants: Chengdu Yiping Medical Science & Technology Co., Ltd., Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Keliang Liu, Yuanjun Liang, Xiaoyu Xu, Sicheng Li
-
Publication number: 20130231369Abstract: Provided are N-[(4-hydroxypiperidin-4-yl)methyl]pyridin-2(1H)-one derivatives represented by formula I, stereoisomers, pharmaceutically acceptable salts or solvates thereof. The above compounds have the dual activities of 5-hydroxytryptamine 1A receptor ligand and selective serotonin reuptake inhibitor. The preparation methods of the above compounds, the uses of these compounds for the prevention or treatment of nervous system diseases related to 5-hydroxytryptamine system dysfunction and the pharmaceutical compositions containing these compounds are also provided.Type: ApplicationFiled: April 8, 2011Publication date: September 5, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Yunfeng Li, Rifang Yang, Youzhi Zhang, Yongzhen Li, Zengliang Jin, Peng Li, Li Yuan, Liuhong Yun, Nan Zhao, Cheng Zhang, Xiaodan Xu, Rusheng Zhao, Hongxia Chen, Rui Xue, Juanjuan Qin, Zhenzhen Wang, Jiazhi Yao
-
Publication number: 20130203754Abstract: Disclosed are 2-arylimidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R1, R2, R3 and R4 are defined as in the specification.Type: ApplicationFiled: June 9, 2011Publication date: August 8, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Rifang Yang, Yunfeng Li, Yongzhen Li, Nan Zhao, Liuhong Yun, Juanjuan Qin, Zhongyao Feng, Youzhi Zhang